The invention encompasses novel methods of operating electrochemical sensors such as aptamer-based sensors to analyze complex samples, such as flowing whole blood both in vitro or in vivo. In such environments, electrochemical sensors are often subject to drift, which complicates the interpretation of sensor output in terms of target concentration. The method of the invention utilizes a dual-reporter recognition element that generates a first, sensing current that is responsive to target binding and to environmental factors and a second, reference current that is only affected by environmental factors. The reference current provides information about environmentally-induced drift, which allows the drift effect to be subtracted out. By removing drift artifacts, electrochemical sensors may be deployed to analyze complex samples, such as whole blood, in vivo.

The invention encompasses novel methods of operating electrochemical sensors such as aptamer-based sensors to analyze complex samples, such as flowing whole blood both in vitro or in vivo. In such environments, electrochemical sensors are often subject to drift, which complicates the interpretation of sensor output in terms of target concentration. The method of the invention utilizes a dual-reporter recognition element that generates a first, sensing current that is responsive to target binding and to environmental factors and a second, reference current that is only affected by environmental factors. The reference current provides information about environmentally-induced drift, which allows the drift effect to be subtracted out. By removing drift artifacts, electrochemical sensors may be deployed to analyze complex samples, such as whole blood, in vivo.

Provided herein are methods and compositions to determine the efficacy of a nucleic acid pre-amplification reaction.

Disclosed are methods for determining copy number variation (CNV) associated with a variety of medical conditions. In some embodiments, methods are provided for determining copy number variation (CNV) of fetuses using maternal samples comprising maternal and fetal cell free DNA. In some embodiments, methods are provided for determining CNVs associated with a variety of medical conditions. Some embodiments disclosed herein provide methods to improve the sensitivity and/or specificity of sequence data analysis by deriving a fragment size parameter, such as a size-weighted coverage or a fraction of fragments in a size range. In some embodiments, the fragment size parameter is adjusted to remove within-sample GC-content bias. In some embodiments, removal of within-sample GC-content bias is based on sequence data corrected for systematic variation common across unaffected training samples. Also disclosed are systems and computer program products for evaluation of CNV of sequences of interest.

Disclosed are methods for determining copy number variation (CNV) associated with a variety of medical conditions. In some embodiments, methods are provided for determining copy number variation (CNV) of fetuses using maternal samples comprising maternal and fetal cell free DNA. In some embodiments, methods are provided for determining CNVs associated with a variety of medical conditions. Some embodiments disclosed herein provide methods to improve the sensitivity and/or specificity of sequence data analysis by deriving a fragment size parameter, such as a size-weighted coverage or a fraction of fragments in a size range. In some embodiments, the fragment size parameter is adjusted to remove within-sample GC-content bias. In some embodiments, removal of within-sample GC-content bias is based on sequence data corrected for systematic variation common across unaffected training samples. Also disclosed are systems and computer program products for evaluation of CNV of sequences of interest.

The invention provides a method for validating patient-specific oligos using spike-in sequences.

The invention provides a method for validating patient-specific oligos using spike-in sequences.

The present invention relates to the stabilization of micro-RNA molecules. The compositions and methods described herein can advantageously be used for the provision of internal control and standard microRNAs for inclusion into kits, useful for the normalized, relative or absolute quantification of a microRNA in a biological fluid.

The present invention relates to the stabilization of micro-RNA molecules. The compositions and methods described herein can advantageously be used for the provision of internal control and standard microRNAs for inclusion into kits, useful for the normalized, relative or absolute quantification of a microRNA in a biological fluid.

The present invention relates to a method of typing a microbiome for having a desirable or undesirable signature, comprising analyzing the composition of the population of microorganisms in the microbiome based on taxonomic variation in the DNA sequence of the microbial 16S-23S rRNA internal transcribed spacer (ITS) regions in the genomic DNA of the microorganisms, wherein the sequences of conserved DNA regions comprised in the 16S and 23S rRNA sequences flanking said ITS region in the genome of the microorganisms comprise primer binding sites for amplification of the ITS regions.